Company / PP&E (Net)
Tango Therapeutics, Inc. PP&E (Net) History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$6.9M
FY2025
5-year range
$4.8M / $10.9M
FY2021-FY2025
Trend
-15.2%
vs FY2024
Sector context
#104 of 193
Health Care
What the data says
At $7M, Tango Therapeutics, Inc.'s pp&e (net) ranks #104 of 193 in the Health Care sector. PP&E (Net) has declined for 3 consecutive years, from $11M in FY2022 to $7M in FY2025.
Based on SEC 10-K filings.
$7M in FY2025 with a 5-year CAGR of +12.4%.
Declined from $10M to $7M over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- -14.2%
- 5-Year CAGR
- +12.4%
- 10-Year CAGR
- -
Sector benchmark
#104 of 193 in Health CareTop 54% of 193This company $6.9M Sector average $777.6M
▼
-99.1% below sector average
Key checks
Key Insights
- Tango Therapeutics, Inc.'s pp&e (net) has declined for 3 consecutive years.
- 5-year CAGR of +12.4%, indicating consistent growth.
- In FY2025, pp&e (net) decreased 15.2% year-over-year.
- Ranks #104 out of 193 companies in the Health Care sector.
Company context
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $6.9M | -15.2% |
| FY2024 | $8.1M | -18.2% |
| FY2023 | $9.9M | -9.0% |
| FY2022 | $10.9M | +125.2% |
| FY2021 | $4.8M | +26.4% |
| FY2020 | $3.8M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026